PubMed · 2052290
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J W Kalenak. 1991. More ocular elasticity?. https://doi.org/10.1016/s0161-6420(13)31538-3
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
PURPOSE: The use of metal oxide-silicon field effect transistors (MOSFETs) as clinical dosimeters is demonstrated for a number of patients with targets at different clinical sites. METHODS AND MATERIALS: Commercially available MOSFETs were characterized for energy response, angular dependency of response, and effect of accumulated dose on sensitivity and some inherent properties of MOSFETs. The doses determined both by thermoluminescence dosimetry (TLD) and MOSFETs in clinical situation were evaluated and compared to expected doses determined by calculation. RESULTS: It was observed that a standard calibration of 0.01 Gy/mV gave MOSFET determined doses which agreed with expected doses to within 5% at the 95% confidence limit for photon beams from 6 to 25 MV and electron beams from 5 to 14 MeV. An energy-dependent variation in response of up to 28% was observed between two orientations of a MOSFET. The MOSFET doses compared very well with the doses estimated by TLDs, and the patients tolerated MOSFETs very well. A standard deviation of 3.9% between expected dose and MOSFET determined dose was observed, while for TLDs the standard deviation was 5.1%. The advantages and disadvantages of using MOSFETs for clinical dosimetry are discussed in detail. CONCLUSION: It was concluded that MOSFETs can be used as clinical dosimeters and can be a good alternative to TLDs. However, they have limitations under certain clinical situations.
The magnitude of errors that can arise in practice from the limitations of the least squares method of calibration is estimated. Data generated from y = xn (0.7 < or = n < or = 1.3 and 1 < or = x < or = 30, or < or = 60) was analysed by least squares regression. Each y-value was then presented to the linear model and an x-value predicted. The relative errors on small x-values reached 70% of the concentration value even when r2 exceeded 0.999. Estimates of the errors on each predicted x-value, determined from the standard errors of the slope and intercept failed to reveal large errors at small x-values. Reducing the range over which linear regression is performed improved the errors. Other data sets with a heteroscedastic error distribution show that linear regression by least squares can also lead to the rejection of methods that performed sufficiently well for their application. Heteroscedastic data may be treated by repeated measurements at the lower end of the range. Data from a validation of an HPLC method for isoflavones in legumes is used to show the errors in recovery when a check sample is presented to the instrument using a calibration which satisfies the linearity tests. It is recommended that both y- and relative x-residuals are inspected. It is proposed that over-reliance on linear calibration supported by r2 may make a major contribution to large, hitherto unexplained, inter-laboratory errors.
A rapid, selective, sensitive and reproducible reversed-phase high-performance liquid chromatography (HPLC) procedure for the quantitative determination of pyrimethamine (PYR) in plasma is described. The procedure involved the two-step extraction of PYR and the internal standard, quinine (QN) with acetonitrile and dichloromethane at basic pH. Chromatographic separation consisted of the mobile phase (methanol-water containing 0.005 M octanesulfonic acid, 50:50, v/v) running through the column (Techopak-10 C18) at a flow-rate of 1.6 ml/min. Detection was at UV wavelength of 240 nm. The mean recoveries of PYR and QN at a concentration range of 50 and 500 ng/ml were 98.9 and 89%, and 94.7 and 96% for PYR and QN. The within-day coefficients of variation were 2.1-5.1% for PYR and 5.9% for QN. The day-to-day coefficients of variation were 2.1-4.1% for PYR and 5% for QN. The minimum detectable concentrations for PYR and QN in plasma were 3 and 10 ng/ml. The method was found to be suitable for use in clinical pharmacokinetic study.